Positive Interim Efficacy Analysis of Ph 2 Trial of ENV105 in Advanced Prostate Cancer with Median PFS of Over One Year Announced September 23, 2025
Patients With Aggressive Brain and Advanced Liver Cancers Treated with PIC monotherapy Reach Five Years of Durable RFS September 23, 2025
Final results from OPTIMIZE-1 trial of mitazalimab – mFOLFIRINOX combo in 1L metastatic pancreatic cancer patients announced September 23, 2025
PADCEV™ + KEYTRUDA™ combo Significantly Improves Survival before and after SOC (surgical cystectomy) in cisplatin-ineligible MIBC patients September 16, 2025
Asia cohort of Ph 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) achieved statistically significant OS improvement vs osimertinib in EGFRm NSCLC September 16, 2025
Plixorafenib demonstrated mPFS of 64 months and a CBR of 85.7% in patients with MAPKi-naïve BRAF V600-mutated papillary thyroid cancer September 16, 2025
Rezatapopt Monotherapy Interim Data From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced September 16, 2025
WCLC 2025: Final Analysis of Firmonertinib Monotherapy Data from Ph 1b Study in EGFR PACC Mutant NSCLC presented September 16, 2025
WCLC 2025: Libtayo + chemo demonstrates a more than double 5yr OS rate of 19.4% vs 8.8% with chemo alone in NSCLC September 16, 2025
WCLC 2025: Cadonilimab – Pulocimab Combo Shows Promising Results in IO-Resistant NSCLC September 16, 2025
WCLC 2025: Updated efficacy and safety data presented from Ph 2b REZILIENT1 trial of zipalertinib in EGFRm, amivantamab-ref NSCLC patients September 16, 2025
Positive efficacy data announced from Ph 2 trial of THIO-101 & cemiplimab (Libtayo®) in NSCLC patients who had failed two or more SoC therapy regimens September 16, 2025
Ph 3 Trial of BNT323/DB-1303 Met Primary Endpoint of PFS in HER2+ve Metastatic or Unresectable Breast Cancer September 10, 2025
Tagrisso + chemo demonstrated a median OS of nearly four years in global Ph 3 FLAURA2 trial in EGFR-mutated advanced NSCLC September 10, 2025
Jaypirca significantly improved PFS in patients with treatment-naïve CLL/SLL in the Ph 3 BRUIN CLL-313 study September 9, 2025
Epcoritamab Demonstrates High Response Rates, Safe Outpatient Use in Ph 2 EPCORE® NHL-6 Study in DLBCL September 9, 2025
Survival benefit for bemarituzumab + chemo in 1L gastric cancer attenuates at final analysis September 9, 2025
Robust 24-month CR rate of 41.8% observed for cretostimogene monotherapy in BCG-unresponsive high-risk NMIBC patients September 9, 2025
Positive Data From Ph 1/2 Combo Trial of IDE397 and Trodelvy® in MTAP-Deletion Urothelial Cancer Announced September 9, 2025
In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current SOC September 9, 2025
Positive Interim Ph 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma Announced September 9, 2025
WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets September 9, 2025
WCLC 2025: RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in 1L EGFRm NSCLC September 9, 2025
WCLC 2025: Longer-Term Follow-Up of Patients Showed Improving, Favorable Trend in OS in Ph 3 HARMONi Clinical Trial for Ivonescimab + Chemo in 2L+ EGFRm NSCLC September 9, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
